The case for & against
Bull & Bear analysis
Bearish
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a biotechnology company focused on developing innovative live biotherapeutic solutions to tackle serious infections and inflammatory diseases, particularly in immunocompromised patients. Notably, the company is advancing its lead product candidate, SEER-155, aimed at preventing bacterial bloodstream infections (BSIs) in high-risk populations undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). With a commitment to addressing critical unmet medical needs, Seres is striving to carve out a significant market position in the field of microbiome-based therapeutics.
Bull says
- ↑SEER-155 delivered a 77% relative risk reduction in BSIs versus placebo
- ↑Breakthrough Therapy and QIDP designations expedite regulatory review
- ↑$155 M from Voust sale boosts cash runway into Q4 2025
- ↑Live biotherapeutic MoA tackles infection root causes versus antibiotics
- ↑Potential to expand SEER-155 into broader immunocompromised and cancer cohorts
- ↑Positive analyst revisions, strategic leverage use and healthy liquidity support growth
Bear says
- ↓Net loss widened to $51 M in Q3 2024 from $41 M a year earlier
- ↓Cash of $66.8 M funds ops through Q4 2025 but may require further capital
- ↓Negative earnings yield and weak profitability underline cash‐flow risks
- ↓Phase II timelines could slip without a development partner
- ↓Short interest rising and small size limit competitive and financing flexibility
- ↓Market adoption of SEER-155 remains unproven, raising long-term return doubts
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 07-15-2026bullish
Transcript signals
Bull points
- We were very pleased with the efficacy results. Patients administered SEER-155 experienced a significantly lower rate of bacterial bloodstream infection than the placebo group, as measured through HSCT Day 100. in the SEER 155 arm, two out of 20 patients experienced a BSI versus six out of 14 in the placebo arm, resulting in a highly meaningful relative risk reduction of approximately 77%.
- And we believe this result is very clinically meaningful.
- Additionally, SIR-155 was generally well tolerated. This was especially reassuring given that the patients in the study were highly immunocompromised. No serious adverse events were attributed to SEER 155, and no SEER 155 species were identified in any cultures from any subjects.
Bear points
- Ceres reported a net loss from continuing operations of $51 million for the third quarter as compared to $41 million for the same period in 2023. The higher loss is primarily the result of a loss of $23.4 million associated with the extinguishment of the oak tree debt.
- research and development expenses for the third quarter were $16.5 million compared with $25.2 million for the same period in 2023. The year-over-year decrease was primarily driven by lower personnel costs as a result of the restructuring plan announced in the fourth quarter of last year and cost reduction efforts resulting in overall lower operating costs such as contractors and consultants.
- General and administrative expenses in the continuing operations were $12.7 million for the third quarter, compared with $19.4 million for the same period in 2023. The decrease was primarily driven by lower personnel costs, again, as a result of the aforementioned restructuring plan, and lower headcount-related operating costs, such as IT, along with lower professional fees.
Read full transcript analysis ›